Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Tactic In ANDA Litigation: Novo Blocks Generic Prandin By Changing Its Patent Use Code

Executive Summary

Novo Nordisk succeeded in an unusual maneuver in blocking Caraco Pharmaceutical from getting a generic version of its blood glucose-lowering drug Prandin (repaglinide) on the market. It changed the use code on the patent covering the drug in combination with metformin so that Caraco could not get approval for a monotherapy
Advertisement

Related Content

Patent Use Codes For Brands Can Be Challenged By Generics, Supreme Court Rules
Patent Use Code Arguments At Supreme Court Focus On Role Of FDA In Prandin Patent Dispute
Patent Use Codes: Will Supreme Court Curb Carve-outs Or Spawn Suits?
Supreme Court To Consider Patent Use Codes, But At Best Can Give Generic Firms A Hunting License
Losing The War? Novo's Prandin Patent Ruled Invalid After Generics Cleverly Blocked At FDA
Caraco Seeks Supreme Court Intervention In Its Prandin Patent Use Code Battle With Novo
Patent Use Codes May Still Block Generics As FDA Looks For Alternatives
"The Next Best Way To Block Generics" May Be Novo's Patent Use Code Switch
Teva Launches Generic Cozaar/Hyzaar With Market Exclusivity As FDA Seeks Court Action To Permit Other Entrants
Teva Launches Generic Cozaar/Hyzaar With Market Exclusivity As FDA Seeks Court Action To Permit Other Entrants

Topics

Advertisement
UsernamePublicRestriction

Register

PS052140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel